Table 2 Adjuvant treatment regimens and prognosis of included patients with different pathological types

n

396

34

106

34

Chemotherapy, n (%)

 < 0.001

0.052

 < 0.001

 < 0.001

 Yes

165 (41.7%)

20 (58.8%)

81 (76.4%)

27 (79.4%)

 No

231 (58.3%)

14 (41.2%)

25 (23.6%)

7 (20.6%)

Radiotherapy, n (%)

 < 0.001

 < 0.001

 < 0.001

 < 0.001

 Yes

36 (9.1%)

11 (32.4%)

43 (40.6%)

10 (29.4%)

 No

360 (90.9%)

23 (67.6%)

63 (59.4%)

24 (70.6%)

OS, n (%)

 < 0.001

 < 0.001

 < 0.001

1.000

 Alive

384 (97%)

25 (73.5%)

81 (76.4%)

33 (97.1%)

 Dead

12 (3%)

9 (26.5%)

25 (23.6%)

1 (2.9%)

 OS-time(months), median (IQR)

55.65 (46.42, 71.13)

38.02 (27.36, 55.58)

36.83 (25.48, 60.08)

45.87 (34.88, 62.93)

 < 0.001

 < 0.001

 < 0.001

0.001

PFS, n (%)

 < 0.001

 < 0.001

 < 0.001

0.227

 Stable

380 (96%)

24 (70.6%)

75 (70.8%)

31 (91.2%)

 Recurrent

9 (2.3%)

5 (14.7%)

11 (10.4%)

2 (5.9%)

 Unknown

7 (1.8%)

5 (14.7%)

20 (18.9%)

1 (2.9%)

PFS-time(months), median (IQR)

55.90 (46.43, 71.13)

41.10 (31.33, 56.53)

40.93 (26.53, 62.53)

45.67 (36.83, 62.97)

 < 0.001

 < 0.001

 < 0.001

 < 0.001